Drug Profile
GEN 009
Alternative Names: GEN-009Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Genocea Biosciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 May 2022 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC)
- 20 May 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (SC)
- 19 Apr 2022 Genocea Biosciences completes a phase I/IIa trial in Solid Tumors in USA (NCT03633110)